Pentoxifylline ameliorates non-alcoholic fatty liver disease in hyperglycaemic and dyslipidaemic mice by upregulating fatty acid β-oxidation

@inproceedings{Ye2016PentoxifyllineAN,
  title={Pentoxifylline ameliorates non-alcoholic fatty liver disease in hyperglycaemic and dyslipidaemic mice by upregulating fatty acid β-oxidation},
  author={Jia-Hung Ye and Jung Chao and M Chang and Wen-Huang Peng and Hao-Yuan Cheng and J W Liao and Li-Heng Pao},
  booktitle={Scientific reports},
  year={2016}
}
Nonalcoholic fatty liver disease (NAFLD), which includes simple steatosis, steatohepatitis, fibrosis, and cirrhosis, is characterised by abnormal fat accumulation in the liver in the absence of excessive alcohol intake. In patients with type 2 diabetes (T2D), concurrent NAFLD might increase the risk of chronic kidney disease and the mortality rate. Although… CONTINUE READING